Payment overview · 2025
General Payments
$778.84
11 reported records · 6 companies
Healthcare provider profile · identity verified
Randolph P Sumner, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROME, GA · NPI 1700871555
Verified facts
What the public records show
CMS Open Payments records show Randolph P Sumner, MD received $778.84 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $315.60 | 40.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $249.98 | 32.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.46 | 16.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.18 | 5.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.14 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.48 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $778.84 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $249.98 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $160.23 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.78 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 222 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
222 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 93 |
| Omeprazole | Omeprazole | 301 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 298 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 65 |
| Farxiga | Dapagliflozin Propanediol | 222 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 56 |
| Ezetimibe | Ezetimibe | 204 | 51 |
| Metformin Hcl | Metformin Hcl | 178 | 55 |
| Furosemide | Furosemide | 175 | 52 |
| Famotidine | Famotidine | 160 | 46 |
| Alprazolam | Alprazolam | 155 | 21 |
| Gabapentin | Gabapentin | 151 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 40 |
| Lorazepam | Lorazepam | 138 | 23 |
| Potassium Chloride | Potassium Chloride | 136 | 43 |
| Eliquis | Apixaban | 134 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 17 |
| Lisinopril | Lisinopril | 132 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 34 |
| Losartan Potassium | Losartan Potassium | 126 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 39 |
| Trazodone Hcl | Trazodone Hcl | 116 | 29 |
| Montelukast Sodium | Montelukast Sodium | 108 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 28 |
| Carvedilol | Carvedilol | 101 | 28 |
| Allopurinol | Allopurinol | 99 | 24 |
| Spironolactone | Spironolactone | 99 | 24 |
| Clonazepam | Clonazepam | 91 | 14 |
| Glipizide Er | Glipizide | 90 | 23 |
| Meloxicam | Meloxicam | 85 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 18 |
| Ozempic | Semaglutide | 67 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 29 |
| Mirtazapine | Mirtazapine | 63 | 13 |
| Synthroid | Levothyroxine Sodium | 62 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 18 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Prednisone | Prednisone | 57 | 36 |
| Valsartan | Valsartan | 57 | 16 |
| Metformin Hcl Er | Metformin Hcl | 56 | 18 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Aripiprazole | Aripiprazole | 54 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 17 |
| Pregabalin | Pregabalin | 53 | 13 |
| Tramadol Hcl | Tramadol Hcl | 52 | 14 |
| Donepezil Hcl | Donepezil Hcl | 50 | 15 |
| Methocarbamol | Methocarbamol | 48 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Fenofibrate | Fenofibrate | 46 | 13 |
| Simvastatin | Simvastatin | 45 | 13 |
| Vascepa | Icosapent Ethyl | 45 | 11 |
| Cephalexin | Cephalexin | 44 | 33 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Kerendia | Finerenone | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 13 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 40 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 15 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Finasteride | Finasteride | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 19 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Klor-Con M10 | Potassium Chloride | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Verapamil Sr | Verapamil Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Colchicine | Colchicine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 11 |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $778.84 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, QULIPTA, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error